Health and Me

Rachel V Thomas

Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Ads: Should GLP-1 Users Be Concerned?

The makers of blockbuster weight-loss drugs <span>Novo Nordisk</span> and <span>Eli Lilly</span> are locked in a legal battle after Novo accused its rival of misleading advertising by claiming its obesity and diabetes medicines outperform Novo's treatments.

Danish drugmaker <a href="https://www.healthandme.com/health-news/novo-nordisk-launches-awiqli-in-india-all-about-the-worlds-first-once-weekly-insulin-article-155014550" data-type="tilCustomLink">Novo Nordisk</a> has filed a lawsuit against Eli Lilly in the US District Court in New Jersey, alleging the company violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns for its obesity drug Zepbound and diabetes treatment Mounjaro, media reports said.

<h2>Novo Alleges Ads Used Outdated Comparisons</h2>

<ul><li>Compared the highest approved doses of <span rel="noindex">Zepbound and Mounjaro</span> with lower doses of Novo's Wegovy and <a href="https://www.healthandme.com/health-news/serena-williams-lost-34-pounds-with-the-help-of-a-glp-1-drug-but-its-not-ozempic-article-154817684" data-type="tilCustomLink">Ozempic</a>.</li><li>Omitted data on the newer 7.2 mg dose of Wegovy, which, as per Novo, delivers greater weight loss.</li><li>Relied on older clinical trial data that no longer reflects current approved dosing.</li></ul>

"The ads are maliciously and deceptively false because Lilly knowingly cites outdated clinical trials that compare the highest doses of the Lilly medicines to lower doses of Novo Nordisk's medicines," Novo said in its complaint.

<strong>Also read: </strong><a href="https://www.healthandme.com/health-news/novo-nordisks-glp-1-drug-wegovy-approved-for-fatty-liver-disease-in-india-article-155115995" data-type="tilCustomLink">Novo Nordisk's GLP-1 Drug Wegovy Approved for Fatty Liver Disease in India</a>

Eli Lilly rejected the allegations, saying its advertisements accurately reflect findings from its SURMOUNT-5 clinical trial.

<ul><li>The study, completed in 2024, compared 10 mg and 15 mg doses of Zepbound with 1.7 mg and 2.4 mg doses of Wegovy.</li><li>Novo's 7.2 mg Wegovy received US FDA approval only in March 2026, after the trial had concluded.</li></ul>

"Rather than compete on the merits of its products, Novo is asking a court to stop Lilly from communicating the results of that trial," an Eli Lilly spokesperson said. "We will continue to focus on the science and defend against this lawsuit vigorously."

<h2>Battle For Expanding Obesity Market</h2>

Omicron RF.5 Explained: Is the New COVID Variant More Dangerous? | COVID-19 India

The lawsuit comes as Novo Nordisk and Eli Lilly compete for dominance in the rapidly expanding US obesity drug market, which analysts expect to exceed $100 billion by 2030.

Both companies dominate the GLP-1 medicine market:

<ul><li>Novo Nordisk's medicines contain semaglutide.</li><li>Eli Lilly's medicines contain tirzepatide.</li></ul>

<ul><li>Mimic the GLP-1 hormone.</li><li>Slow digestion.</li><li>Help regulate blood sugar.</li><li>Suppress appetite.</li></ul>

Beyond weight loss, studies have shown that GLP-1 medicines can reduce the risk of major cardiovascular events, including heart attack and stroke, and may also lower the risk of several cancers.

In December 2025, the World Health Organization (WHO) issued its first guideline on the use of GLP-1 therapies for obesity, describing the condition as a chronic, relapsing disease affecting more than 1 billion people worldwide. It recommends:

<ul><li> GLP-1 therapies may be used for long-term obesity treatment in adults, excluding pregnant women.</li><li>Treatment should be combined with structured lifestyle interventions, including a healthy diet, regular physical activity, and behavioral support to improve outcomes.</li></ul>

For now, patients are unlikely to be affected. The lawsuit does not challenge the safety, effectiveness, or FDA approval of the medicines. Instead, it focuses solely on how Eli Lilly marketed its products.

Patients prescribed the medicines Wegovy and Ozempic (Novo Nordisk) or Zepbound and Mounjaro (Eli Lilly) can continue taking them as directed. 

Any outcome of the case is more likely to influence how pharmaceutical companies advertise and compare their medicines than the availability of these treatments.

Health Conditions A-Z

health

novo-nordisk-sues-eli-lilly-over-weight-loss-drug-ads-should-glp-1-users-be-concerned

Novo Nordisk

Eli Lilly

Weight Loss Drugs

GLP 1 drugs

ozempic and wegovy

Zepbound and Mounjaro

france-becomes-first-eu-nation-to-ban-social-media-for-under-15s-could-this-help-childrens-mental-health

France Becomes First EU Nation To Ban Social Media For Under-15s; Could This Help Children's Mental Health?

world-brain-day-how-poor-sleep-increases-the-risk-of-neurological-disorders

World Brain Day: How Poor Sleep Increases The Risk Of Neurological Disorders

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

The makers of blockbuster weight-loss drugs Novo Nordisk and Eli Lilly are locked in a legal battle after Novo accused its rival of misleading advertising by claiming its obesity and diabetes medicines outperform Novo's treatments.Danish drugmaker Novo Nordisk has filed a lawsuit against Eli Lilly in the US District Court in New Jersey, alleging the company violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns for its obesity drug Zepbound and diabetes treatment Mounjaro, media reports said.Novo Alleges Ads Used Outdated ComparisonsNovo claims Lilly's advertisements:Compared the highest approved doses of Zepbound and Mounjaro with lower doses of Novo's Wegovy and Ozempic.Omitted data on the newer 7.2 mg dose of Wegovy, which, as per Novo, delivers greater weight loss.Relied on older clinical trial data that no longer reflects current approved dosing."The ads are maliciously and deceptively false because Lilly knowingly cites outdated clinical trials that compare the highest doses of the Lilly medicines to lower doses of Novo Nordisk's medicines," Novo said in its complaint.Also read: Novo Nordisk's GLP-1 Drug Wegovy Approved for Fatty Liver Disease in IndiaWhat Did Eli Lilly Say Eli Lilly rejected the allegations, saying its advertisements accurately reflect findings from its SURMOUNT-5 clinical trial.According to the company:The study, completed in 2024, compared 10 mg and 15 mg doses of Zepbound with 1.7 mg and 2.4 mg doses of Wegovy.Novo's 7.2 mg Wegovy received US FDA approval only in March 2026, after the trial had concluded."Rather than compete on the merits of its products, Novo is asking a court to stop Lilly from communicating the results of that trial," an Eli Lilly spokesperson said. "We will continue to focus on the science and defend against this lawsuit vigorously."Battle For Expanding Obesity Market      The lawsuit comes as Novo Nordisk and Eli Lilly compete for dominance in the rapidly expanding US obesity drug market, which analysts expect to exceed $100 billion by 2030.Both companies dominate the GLP-1 medicine market:Novo Nordisk's medicines contain semaglutide.Eli Lilly's medicines contain tirzepatide.These medicines:Mimic the GLP-1 hormone.Slow digestion.Help regulate blood sugar.Suppress appetite.Beyond weight loss, studies have shown that GLP-1 medicines can reduce the risk of major cardiovascular events, including heart attack and stroke, and may also lower the risk of several cancers.WHO Guidance on GLP-1 TherapiesIn December 2025, the World Health Organization (WHO) issued its first guideline on the use of GLP-1 therapies for obesity, describing the condition as a chronic, relapsing disease affecting more than 1 billion people worldwide. It recommends: GLP-1 therapies may be used for long-term obesity treatment in adults, excluding pregnant women.Treatment should be combined with structured lifestyle interventions, including a healthy diet, regular physical activity, and behavioral support to improve outcomes.Will Patients Be Affected?For now, patients are unlikely to be affected. The lawsuit does not challenge the safety, effectiveness, or FDA approval of the medicines. Instead, it focuses solely on how Eli Lilly marketed its products.Patients prescribed the medicines Wegovy and Ozempic (Novo Nordisk) or Zepbound and Mounjaro (Eli Lilly) can continue taking them as directed. Any outcome of the case is more likely to influence how pharmaceutical companies advertise and compare their medicines than the availability of these treatments.

novo nordisk sues eli lilly over weight-loss drug ads: should glp-1 users be concerned?

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Ads: Should GLP-1 Users Be Concerned?

France Becomes First EU Nation To Ban Social Media For Under-15s; Could This Help Children's Mental Health?

Meet Paul Alexander: Longest-Known Polio Survivor Who Lived In An Iron Lung For 70 Years

Hantavirus Claims 3 Lives In Venezuela: What The Rat-borne Virus Does To The Brain

Health Conditions A-Z

France Becomes First EU Nation To Ban Social Media For Under-15s; Could This Help Children's Mental Health?

Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Ads: Should GLP-1 Users Be Concerned?

World Brain Day: How Poor Sleep Increases The Risk Of Neurological Disorders